Page last updated: 2024-08-24

irinotecan and Breast Cancer

irinotecan has been researched along with Breast Cancer in 124 studies

Research

Studies (124)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's15 (12.10)18.2507
2000's42 (33.87)29.6817
2010's50 (40.32)24.3611
2020's17 (13.71)2.80

Authors

AuthorsStudies
Cheng, L; Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC1
LaVoie, EJ; Liu, A; Liu, L; Pilch, DS; Rice, JE; Rzuczek, SG1
Alsherbiny, MA; Bhuyan, DJ; Chang, D; Li, CG; Low, MN1
Chung, YM; Hu, MC; Khan, PP; Larrick, JW; Qiao, Y; Tsai, WB; Wang, H; Yu, B1
Harada, K; Hatanaka, K; Iwanaga, I; Kato, T; Kawamoto, Y; Komatsu, Y; Meguro, T; Nakamura, M; Nakano, S; Oba, K; Okuda, H; Sakamoto, N; Sakata, Y; Sato, A; Uebayashi, M; Yuki, S1
Choi, CH; Lee, HJ1
Johmura, Y; Miyoshi, Y; Nakanishi, M; Ohta, T; Taira Nihira, N; Togashi, Y; Wu, W; Zhu, D; Zhu, J1
Bardia, A; Ciruelos, E; Cortes, J; Dalenc, F; Delaney, R; Fu, O; Jhaveri, KL; Lin, L; Loirat, D; Marmé, F; Pardo, PG; Rugo, HS; Schmid, P; Tolaney, SM; Trédan, O; Verret, W1
Hamilton, E; Jacob, S; Rugo, HS; Shastry, M1
Bai, Y; Gong, J; Huang, D; Ji, C; Li, J; Li, Y; Shen, L; Sun, Y; Wang, X; Wang, Z; Xin, Y; Xu, T; Zhang, X; Zhao, F1
Daldrup-Link, HE1
Abd El-Sadek, I; Lichtenegger, A; Makita, S; Matsusaka, S; Mori, T; Mukherjee, P; Shen, LT; Yasuno, Y1
Ding, Z; Han, J; Hong, J; Liu, M; Liu, Y; Ma, Q; Zhang, H; Zhao, Y1
Cai, Y; Chen, F; Chen, Y; Li, S; Luo, X; Wu, Z1
Anan, K; Furusawa, H; Kai, Y; Kamada, Y; Mitsuyama, S; Miyara, K; Sagara, Y; Tamura, K; Tanaka, M; Tanaka, T; Uga, T1
Anders, C; Belanger, B; Han, HS; Ma, C; Maxwell, F; Moore, Y; Munster, P; Northfelt, DW; Sachdev, JC; Thiagalingam, A; Wang, T; Zhang, B1
Cai, S; Chen, L; Chen, Z; Lu, C; Tong, Y; Wang, M; Wang, Y; Wu, J; Yang, H1
Chen, CC; Chen, CY; Cheng, SF; Chern, CY; Chi, YC; Chiu, YC; Kuo, YT; Lee, WC; Li, YC; Lin, PY; Liou, SJ; Tseng, ST; Tseng, WC; Wang, CA1
Aldrich, J; Alemi, F; Anthony, SP; Arguello, D; Avramovic, S; Baldelli, E; Bellos, A; Carpten, JD; Conrad, A; Craig, DW; Dunetz, B; Gallagher, RI; Hodge, KA; Jahanzeb, M; Kemkes, A; Liotta, LA; Loesch, DM; Northfelt, DW; Petricoin, EF; Pierobon, M; Robert, NJ; Vocila, L; Wojtusiak, J; Wong, S; Wulfkuhle, JD1
Keyvani-Ghamsari, S; Rabbani-Chadegani, A; Sargolzaei, J; Shahhoseini, M1
Sahota, S; Vahdat, LT1
Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ1
Abdel-Rahman, WM; Al-Khayyal, NA; Aravind, SR; Nair, VA; Saber-Ayad, M1
Chen, Z; Li, S; Li, T; Liu, Y; Qin, X; Shen, X; Wu, C; Xie, X; Yang, H1
Ahn, JH; Im, SA; Jung, KH; Kim, HJ; Kim, JH; Kim, SB; Kim, TY; Lee, KH; Lee, KS; Lee, S; Nam, BH; Park, IH; Park, KH; Park, YH; Ro, J; Sim, SH; Sohn, JH1
Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C1
Cheng, R; Li, X; Liu, Z; Lu, A; Sun, N; Tian, Z; Yang, Z; Zhao, C1
Balslev, E; Brünner, N; Ejlertsen, B; Jakobsen, EH; Kümler, I; Nielsen, DL; Stenvang, J1
Chalasani, P; Livingston, RB; Reed, D; Segar, JM; Stopeck, A1
Balslev, E; Brünner, N; Kümler, I; Nielsen, DL; Stenvang, J1
Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J1
Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U1
Brünner, N; Nielsen, DL1
Awada, A; Barrett-Lee, PJ; Chan, S; Chia, YL; Cocquyt, V; Coleman, RE; Garcia, AA; Hamm, JT; Hannah, AL; Hoch, U; Huizing, MT; Jerusalem, GH; Mehdi, A; O'Reilly, SM; Perez, EA; Sideras, K; Young, DE; Zhao, C1
Cao, DY; Dun, JN; Fang, Y; Wang, J; Xiang, B; Xue, GQ; Zhang, L1
Inaba, T; Ishida, K; Kashiwaba, M; Kawagishi, R; Komatsu, H; Matsui, Y; Sugai, T; Uesugi, N; Wakabayashi, G1
Berek, JS; Chung, YM; Guan, M; Hu, MC; Hu, T; Ma, J; Ma, M1
Mishra, MN; Palakurthi, S; Vangara, KK1
Lan, H; Li, Y; Lin, CY1
Hayakawa, Y; Lou, C; Saiki, I; Yokoyama, S1
Balslev, E; Brünner, N; Kümler, I; Nielsen, D; Stenvang, J1
Amzerin, M; Errihani, H; Mokrim, M; Piccart, MJ1
Cuddington, BP; Ketela, T; Moffat, J; Mossman, KL; Workenhe, ST1
Advani, PP; Crozier, JA; Hobday, T; Jaslowski, AJ; LaPlant, B; Moreno-Aspitia, A; Perez, EA1
Adkins, CE; Eldon, MA; Hoch, U; Hye, T; Lockman, PR; Mohammad, AS; Mohan, NK; Nounou, MI; Terrell-Hall, T1
Aluzaite, K; Brünner, N; Damsgaard, B; Do, KN; Foekens, J; Fogh, L; Gajjar, M; Hamerlik, P; Hansen, SN; Jandu, H; Knudsen, BR; Martens, J; Moreira, J; Nielsen, SL; Noer, JB; Pommier, Y; Proszek, J; Schrohl, AS; Smid, M; Stenvang, J; Stougaard, M; Thrane, SW1
Bartlett, JM; Boutros, PC; Braunstein, M; Kalatskaya, I; Krzyzanowski, PM; Liao, L; Lobo, N; Lyttle, N; Marcellus, R; Spears, M; Stein, LD; Taylor, KJ; Twelves, CJ; Yao, CQ1
Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G1
Cardillo, TM; Chang, CH; Goldenberg, DM; Liu, D; Wang, Y; Zalath, M1
Billadeau, DD; Cristofanilli, M; Cryns, VL; Gaisina, I; Giles, F; Jain, S; Kozikowski, A; Mazar, AP; O'Halloran, T; Ugolkov, A; White, K; Zhang, JS1
Abe, N; Abe, S; Aoto, K; Kawana, S; Murakami, F; Ohtake, T; Okano, M; Suzuki, O; Tachibana, K; Takenoshita, S; Tasaki, K1
Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS1
Choi, J; Gump, J; Lacevic, M; Lee, JH; Lush, R; Minton, S; Moulder, S; Munster, P; Neuger, A; Sullivan, D; Valkov, N1
Algeciras-Schimnich, A; O'Kane, DJ; Snozek, CL1
Fujii, S; Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Oota, Y; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Souda, M; Tanaka, K; Yamamoto, Y1
Anderson, DM; Bernath, AM; Gamini, SS; Hillman, DW; Niedringhaus, R; Northfelt, DW; Palmieri, F; Perez, EA; Salim, M; Stella, PJ; Tan, WW1
Choi, K; Rineer, J; Sanmugarajah, J1
Ames, MM; Goetz, MP; Kuffel, MJ; Reinicke, KE1
Fushimi, K; Kumagai, K; Nakano, S; Yamamoto, N1
Arnaud, O; Bates, SE; Boumendjel, A; Di Pietro, A; Dumontet, C; Falson, P; Gèze, A; Guitton, J; Honorat, M; Matera, EL; Payen, L; Stein, WD1
Aoki, M; Fujii, M; Murata, T; Oda, K1
Hede, K1
Azzariti, A; Cantore, M; Cassano, G; Colabufo, NA; Gasparre, G; Iannelli, G; Panaro, MA; Paradiso, A; Porcelli, L; Quatrale, AE; Tommasi, S1
Hayashi, H; Masuda, N; Miyazaki, M; Morinaga, R; Nakagawa, K; Nakayama, T; Nishida, Y; Okamoto, I; Okamoto, W; Sakamoto, J; Satoh, T; Terashima, M; Tokunaga, Y; Tominaga, S; Tsurutani, J; Yamaguchi, M1
Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M1
Aft, RL; Cai, S; Ellis, MJ; Goiffon, RJ; Guo, Z; Hoog, J; Li, S; Lin, L; Ma, CX; Piwnica-Worms, H; Prat, A; Ryan, CE; Schaiff, WT1
Kanomata, N; Kozuka, Y; Kurebayashi, J; Moriya, T; Shimo, T; Sonoo, H; Yamashita, T1
Lee, KS; Nam, BH; Park, IH; Ro, J1
Choi, KC; Choi, KJ; Kim, SU; Yi, BR1
Ambudkar, SV; Bhatnagar, J; Chen, JJ; Chen, WM; Chen, ZS; Lan, P; Ruan, ZX; Shu, C; Sodani, K; Wang, J; Xiao, ZJ; Ye, WC; Zhang, DM1
Bernard, PS; Brenin, CM; Cai, SR; Craig Lockhart, A; Creekmore, AN; Dancey, J; Doyle, LA; Ebbert, M; Ellis, MJ; Fracasso, PM; Guo, Z; Ma, CX; Mwandoro, T; Naughton, MJ; Petroni, GR; Picus, J; Piwnica-Worms, H; Pluard, TJ; Reed, J; Ryan, CE; Watson, M; Yarde, ER1
Huang, J; Mao, W; Shen, Y; Sui, M; Wang, J; Wu, X; Zhang, H1
Shimada, T; Watanabe, A1
Budman, DR1
Agelaki, S; Alexopoulos, A; Ardavanis, A; Georgoulias, V; Kalbakis, K; Karyda, E; Kouroussis, Ch; Malamos, N; Malas, K; Tselepatiotis, E1
Shapiro, CL; Xu, Y1
Bowen, JM; Cummins, AG; Gibson, RJ; Inglis, MR; Keefe, DM1
Botti, G; Capasso, I; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Lapenta, L; Thomas, R; Vallone, P1
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL1
Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y1
Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M1
Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K1
Dakhil, SR; Fitch, TR; Hillman, DW; Ingle, JN; Kardinal, CG; Krook, JE; Kugler, JW; Mailliard, JA; Perez, EA; Rowland, KM; Ryan, JM1
Paukstadt, W1
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M1
Arima, T; Horino, K; Inoue, M; Kaneda, H; Kimura, M; Kuhara, H; Kume, S; Nakano, M; Nishimura, T; Uemura, K1
Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J1
André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C1
Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; D'Aniello, R; De Rosa, V; Di Bonito, M; Frasci, G; Giordano, R; Lapenta, L; Thomas, R; Vallone, P1
Amano, S; Enomoto, K; Negishi, N; Sakurai, K1
Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W1
Drummond, DC; Guo, Z; Hong, K; Kirpotin, DB; Noble, CO; Park, JW1
Fujii, Y; Nakazawa, K; Shuzui, Y; Yoneto, T1
Allen, WL; Galligan, L; Johnston, PG; Longley, DB; Rogers, KM; Sakai, H; Thomas, M; Wilson, TR1
Komatsu, N; Makuuchi, H; Matsui, N; Mukai, M; Nakamura, M; Nakasaki, H; Ninomiya, H; Sato, S; Wakui, K1
Boku, N; Yamazaki, K; Yoshino, T1
Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H1
Allen, J; Kolesar, J; Mrozek, E; Shapiro, CL; Villalona-Calero, M; Young, D1
Hirose, S; Hojo, T; Ikeuchi, S; Isobe, Y; Kinoshita, T; Kubochi, K; Matsumoto, S; Sadako, AT; Shien, T; Terada, K1
Taguchi, T1
Doihara, H; Takashima, S; Yokoyama, N1
Ishida, T; Morimoto, K; Ogawa, M; Ogawa, N; Taguchi, T; Tominaga, T1
Ishida, T; Izuo, M; Nakao, I; Ogawa, M; Oguro, M; Ohkawa, T; Taguchi, T; Tominaga, T; Yoshida, M; Yoshida, Y1
Sinha, BK; Wang, Z1
Keith, WN; McLeod, HL1
Armand, JP; Couteau, C; Terret, C1
Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A1
Rosen, LS1
Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M1
Mangold, G; Manikumar, G; Marty, J; Potter, PM; Vladu, B; Von Hoff, DD; Wadkins, RM; Wall, ME; Wani, MC; Weitman, S1
Cameron, IL; Hardman, WE; Moyer, MP1
Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C1
Baldwin, AS; Cusack, JC; Liu, R1
Ikeda, H; Koshiba, R1
Kinoshita, H; Kou, M; Morimoto, K1
Prescott, LM1
Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ1
Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW1
Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Itoh, K; Minami, H; Saeki, T; Sasaki, Y; Shigeoka, Y1
Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T1
Cummings, J; Jardine, L; Joel, SP; Okorokov, AL; te Poele, RH1
Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T1
Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R1
Furue, H; Hasegawa, K; Hattori, T; Niitani, H; Ohta, K; Taguchi, T; Wakui, A1

Reviews

15 review(s) available for irinotecan and Breast Cancer

ArticleYear
Sacituzumab govitecan: an antibody-drug conjugate.
    Expert opinion on biological therapy, 2017, Volume: 17, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Immunoconjugates; Irinotecan; Neoplasms; Neutropenia; Urologic Neoplasms

2017
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
    Breast cancer research and treatment, 2013, Volume: 138, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; DNA Topoisomerases, Type I; Female; Humans; Irinotecan; Neoplasm Metastasis; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2013
[A Case of Primary Poorly Differentiated/Small Cell Carcinoma of the Breast in a Patient with Von Recklinghausen's Disease].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neurofibromatosis 1

2016
Pharmacogenomics of tamoxifen and irinotecan therapies.
    Clinics in laboratory medicine, 2008, Volume: 28, Issue:4

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 CYP2D6; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen; Treatment Outcome

2008
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).
    International journal of oncology, 2012, Volume: 41, Issue:3

    Topics: Breast Neoplasms; Camptothecin; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Ganciclovir; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Humans; Irinotecan; Prodrugs; Stem Cells; Thymidine Kinase

2012
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
    Cancer investigation, 2002, Volume: 20 Suppl 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome

2002
Rationale for mitomycin and irinotecan use in advanced breast cancer.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:5 Suppl 5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mitomycin; Women's Health

2003
[Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoembryonic Antigen; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Skin Neoplasms

2005
[Bevacizumab (Avastin)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Vascular Endothelial Growth Factor A

2007
[Recent advance in chemotherapy for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:16

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Docetaxel; Female; Humans; Irinotecan; Mitoxantrone; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids

1994
CPT-11: the European clinical development.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms

1996
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms

1998
[Clinical activity spectrum of irinotecan].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome

1998
[Irinotecan hydrochloride for treatment of advanced breast cancers].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58 Suppl

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Topoisomerase I Inhibitors

2000
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
    Seminars in oncology, 2001, Volume: 28, Issue:3 Suppl 10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms

2001

Trials

32 trial(s) available for irinotecan and Breast Cancer

ArticleYear
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
    The oncologist, 2022, 05-06, Volume: 27, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Irinotecan; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Trastuzumab

2022
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 10-10, Volume: 40, Issue:29

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Cyclin-Dependent Kinase 4; Female; Humans; Immunoconjugates; Irinotecan; Middle Aged; Receptor, ErbB-2; Vinorelbine

2022
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Breast (Edinburgh, Scotland), 2022, Volume: 66

    Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Topoisomerase Inhibitors; Triple Negative Breast Neoplasms

2022
Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis.
    Cancer research and treatment, 2023, Volume: 55, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Humans; Irinotecan; Phosphatidylinositol 3-Kinases; Rectal Neoplasms; Trastuzumab

2023
Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
    Breast cancer research and treatment, 2021, Volume: 185, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Irinotecan; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms

2021
Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.
    Molecular oncology, 2022, Volume: 16, Issue:1

    Topics: Breast Neoplasms; Female; Humans; Immunohistochemistry; Irinotecan; Prospective Studies; Treatment Outcome

2022
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    British journal of cancer, 2017, Jun-27, Volume: 117, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting

2017
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
    Cancer research and treatment, 2019, Volume: 51, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Progression-Free Survival; Quality of Life; Taxoids; Treatment Outcome

2019
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
    BMC cancer, 2019, Jun-13, Volume: 19, Issue:1

    Topics: Aged; Antineoplastic Agents; Biomarkers, Pharmacological; Breast Neoplasms; DNA Topoisomerases, Type I; Drug Therapy, Combination; Female; Gene Dosage; Humans; Irinotecan; Middle Aged; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Topoisomerase I Inhibitors; Trastuzumab; Treatment Outcome

2019
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
    The oncologist, 2019, Volume: 24, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors

2019
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
    Breast cancer (Tokyo, Japan), 2015, Volume: 22, Issue:4

    Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Polymorphism, Genetic; Pyridines; Survival Analysis; Tegafur; Treatment Outcome

2015
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Europe; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Polyethylene Glycols; Time Factors; Topoisomerase I Inhibitors; Treatment Outcome; United States

2013
A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with anthracyclines and taxanes.
    Oncology, 2014, Volume: 86, Issue:4

    Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids

2014
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
    BMC cancer, 2015, Feb-21, Volume: 15

    Topics: Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Female; Gene Dosage; Genetic Markers; Humans; Irinotecan; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Topoisomerase I Inhibitors; Treatment Outcome

2015
N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.
    Clinical breast cancer, 2016, Volume: 16, Issue:1

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cetuximab; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids

2016
Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.
    Breast cancer research : BCR, 2016, Feb-06, Volume: 18, Issue:1

    Topics: Adult; Anthracyclines; Apoptosis; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Irinotecan; MCF-7 Cells; Middle Aged; Signal Transduction; Young Adult

2016
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    American journal of clinical oncology, 2008, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome

2008
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
    Cancer, 2008, Nov-15, Volume: 113, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Chromatography, High Pressure Liquid; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged

2008
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome

2010
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
    Breast cancer (Tokyo, Japan), 2013, Volume: 20, Issue:2

    Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Salvage Therapy; Topoisomerase Inhibitors; Young Adult

2013
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:1

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome

2013
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
    Breast cancer research and treatment, 2013, Volume: 137, Issue:2

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Genes, p53; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mutation; Ribosomal Protein S6; Staurosporine; Treatment Outcome

2013
Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study.
    Oncology, 2003, Volume: 64, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Middle Aged; Treatment Outcome

2003
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Recombinant Proteins; Taxoids

2004
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2004
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5

    Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids

2005
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
    Oncology, 2005, Volume: 68, Issue:4-6

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids

2005
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Gene Expression; Humans; Irinotecan; Leukocytes, Mononuclear; Middle Aged; Mitomycin; NAD(P)H Dehydrogenase (Quinone); Neoplasm Metastasis; Polymorphism, Single Nucleotide

2008
[A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:7

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged

1994
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:1

    Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia

1994
[A pilot study of irinotecan hydrochloride for metastatic breast cancer--efficacy as a salvage therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Pilot Projects; Salvage Therapy

2000
[Phase I clinical study of CPT-11. Research group of CPT-11].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms

1990

Other Studies

77 other study(ies) available for irinotecan and Breast Cancer

ArticleYear
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
    Bioorganic & medicinal chemistry, 2008, Aug-15, Volume: 16, Issue:16

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays

2008
Macrocyclic pyridyl polyoxazoles: selective RNA and DNA G-quadruplex ligands as antitumor agents.
    Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; DNA; Drug Screening Assays, Antitumor; G-Quadruplexes; Humans; Ligands; Macrocyclic Compounds; Mice; Mice, Nude; Neoplasm Proteins; Oxazoles; Pyridines; RNA; Xenograft Model Antitumor Assays

2010
Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
    International journal of molecular sciences, 2021, Sep-18, Volume: 22, Issue:18

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cannabidiol; Cell Line, Tumor; Cell Survival; Dactinomycin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Irinotecan; MCF-7 Cells; Paclitaxel; Proteome; Proteomics; Vinorelbine

2021
Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Journal for immunotherapy of cancer, 2021, Volume: 9, Issue:12

    Topics: Animals; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Proliferation; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Irinotecan; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Prognosis; Programmed Cell Death 1 Receptor; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Microenvironment

2021
Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
    BMC cancer, 2022, Apr-23, Volume: 22, Issue:1

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; DNA; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Irinotecan; Multidrug Resistance-Associated Proteins; Neoplasm Proteins

2022
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
    Breast cancer (Tokyo, Japan), 2022, Volume: 29, Issue:6

    Topics: Antigens, Neoplasm; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Irinotecan; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Tamoxifen; Transcription Factors; Triple Negative Breast Neoplasms

2022
Pretherapy Ferumoxytol-enhanced MRI for Metastatic Breast Cancer: A New Approach for Predicting Tumor Delivery of Macromolecular Therapeutics?
    Radiology. Imaging cancer, 2023, Volume: 5, Issue:2

    Topics: Breast Neoplasms; Contrast Media; Female; Ferrosoferric Oxide; Humans; Irinotecan; Magnetic Resonance Imaging

2023
Label-free drug response evaluation of human derived tumor spheroids using three-dimensional dynamic optical coherence tomography.
    Scientific reports, 2023, 09-16, Volume: 13, Issue:1

    Topics: Algorithms; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Humans; Irinotecan; Paclitaxel; Tomography, Optical Coherence

2023
Novel carrier-free nanoparticles composed of 7-ethyl-10-hydroxycamptothecin and chlorin e6: Self-assembly mechanism investigation and in vitro/in vivo evaluation.
    Colloids and surfaces. B, Biointerfaces, 2020, Volume: 188

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chlorophyllides; Drug Screening Assays, Antitumor; Irinotecan; Mice; Molecular Dynamics Simulation; Nanoparticles; Particle Size; Photochemotherapy; Photosensitizing Agents; Porphyrins; Surface Properties; Thermodynamics

2020
Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
    Colloids and surfaces. B, Biointerfaces, 2020, Volume: 189

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Irinotecan; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Molecular Structure; Particle Size; Phosphorylcholine; Polymers; Prodrugs; Surface Properties

2020
Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer.
    Anticancer research, 2020, Volume: 40, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Pilot Projects; Progression-Free Survival; Tegafur

2020
Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
    Theranostics, 2021, Volume: 11, Issue:4

    Topics: Animals; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Proliferation; Female; Humans; Hypoglycemic Agents; Immunotherapy; Irinotecan; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Nanoparticles; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021
Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.
    International journal of molecular sciences, 2021, Apr-23, Volume: 22, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Breast Neoplasms; Cell Proliferation; Curcumin; DNA Damage; DNA Repair; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Irinotecan; Mice; Mice, Nude; Mutation; Rad52 DNA Repair and Recombination Protein; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021
Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:4

    Topics: Acetylation; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Irinotecan; Matrix Metalloproteinase 9; MCF-7 Cells; Poly(ADP-ribose) Polymerases

2017
Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
    World journal of gastroenterology, 2017, May-21, Volume: 23, Issue:19

    Topics: Animals; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Doxorubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; HeLa Cells; Humans; Irinotecan; MCF-7 Cells; Mice, Knockout; Mutation; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53

2017
Irinotecan/IR-820 coloaded nanocomposite as a cooperative nanoplatform for combinational therapy of tumor.
    Nanomedicine (London, England), 2018, 03-01, Volume: 13, Issue:6

    Topics: Animals; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Delivery Systems; Female; Humans; Indocyanine Green; Irinotecan; MCF-7 Cells; Mice; Nanocomposites; Silicon Dioxide; Xenograft Model Antitumor Assays

2018
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
    Thoracic cancer, 2018, Volume: 9, Issue:5

    Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome

2018
Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells.
    Molecular pharmaceutics, 2018, 08-06, Volume: 15, Issue:8

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Drug Synergism; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplastic Stem Cells; Prodrugs; Theranostic Nanomedicine; Xenograft Model Antitumor Assays

2018
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:5

    Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia

2013
Etirinotecan pegol: an option for late-stage breast cancer?
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Breast Neoplasms; Camptothecin; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Polyethylene Glycols; Topoisomerase I Inhibitors

2013
PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
    European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:24

    Topics: Animals; Bone Marrow; Breast Neoplasms; Camptothecin; Cations; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Lipids; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Surface Properties; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays

2013
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
    Scientific reports, 2014, Jul-24, Volume: 4

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Irinotecan; Metformin; Mice, Nude; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Tumor Burden; Xenograft Model Antitumor Assays

2014
Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Breast Neoplasms; Camptothecin; Carboxylic Ester Hydrolases; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mutation; Neoplasm Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured

2014
Irinotecan as a palliative therapy for metastatic breast cancer patients after previous chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:24

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate

2014
Selective anticancer activity of hirsutine against HER2‑positive breast cancer cells by inducing DNA damage.
    Oncology reports, 2015, Volume: 33, Issue:4

    Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspases; Cell Line, Tumor; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Irinotecan; MCF-7 Cells; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2

2015
Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
    Journal of medical case reports, 2015, Feb-12, Volume: 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasms; Remission Induction; Topoisomerase I Inhibitors

2015
Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.
    Oncogene, 2016, 05-12, Volume: 35, Issue:19

    Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Gene Knockout Techniques; Genomics; Herpesvirus 1, Human; Humans; Irinotecan; Lentivirus; Oncolytic Virotherapy; Phosphorylation; RNA, Small Interfering; Serine-Arginine Splicing Factors; Virus Replication

2016
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
    BMC cancer, 2015, Oct-13, Volume: 15

    Topics: Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Irinotecan; Luminescent Measurements; Mice; Molecular Structure; Permeability; Tumor Burden; Xenograft Model Antitumor Assays

2015
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
    BMC cancer, 2016, Jan-22, Volume: 16

    Topics: Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; MCF-7 Cells; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Taxoids

2016
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
    The Lancet. Oncology, 2016, Volume: 17, Issue:5

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Long Term Adverse Effects; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin

2016
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression; Humans; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Mice; Stomach Neoplasms; Xenograft Model Antitumor Assays

2016
GSK-3 inhibition overcomes chemoresistance in human breast cancer.
    Cancer letters, 2016, 10-01, Volume: 380, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Female; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Irinotecan; Maleimides; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2016
[Evaluation of irinotecan hydrochloride (CPT-11) and trastuzumab combination therapy as salvage treatment in patients with HER2 overexpressing metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Progression; Humans; Immunotherapy; Irinotecan; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab; Treatment Outcome

2009
Small cell carcinoma of the breast.
    Journal of the National Medical Association, 2009, Volume: 101, Issue:10

    Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Radiotherapy Dosage; Radiotherapy, Adjuvant

2009
Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colony-Forming Units Assay; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; DNA; Drug Synergism; Enzyme Induction; Female; Flavonoids; Humans; Irinotecan; Paclitaxel

2010
[Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:6

    Topics: Adult; Aged; Breast Neoplasms; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Multiple; Humans; Irinotecan; Middle Aged; Neutropenia; Recurrence; Salvage Therapy

2010
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:4

    Topics: Acridines; Acridones; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Irinotecan; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Transplantation, Heterologous

2011
[A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Camptothecin; Carcinoma; Fatal Outcome; Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Respiratory Insufficiency; Tomography, X-Ray Computed

2011
Few positives for triple-negative breast cancer.
    Journal of the National Cancer Institute, 2011, Apr-06, Volume: 103, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Camptothecin; Chemistry, Pharmaceutical; Disease-Free Survival; Epothilones; Female; Genes, BRCA1; Humans; Irinotecan; Parity; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Treatment Outcome; Tubulin Modulators

2011
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
    European journal of pharmacology, 2011, Nov-16, Volume: 670, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biphenyl Compounds; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Synergism; Female; Genomics; Humans; Irinotecan; Kinetics; Multidrug Resistance-Associated Proteins; Necrosis; Neoplasm Proteins; Signal Transduction; Tetrahydroisoquinolines; Topotecan

2011
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Oncology reports, 2012, Volume: 27, Issue:6

    Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin

2012
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    The Journal of clinical investigation, 2012, Volume: 122, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA, Neoplasm; Female; Genes, cdc; Genes, erbB-2; Genes, p53; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Receptors, Estrogen; Receptors, Progesterone; Staurosporine; Thiophenes; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays

2012
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Breast cancer (Tokyo, Japan), 2014, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Irinotecan; Neoplastic Stem Cells; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Receptor, ErbB-2

2014
BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
    Molecular pharmaceutics, 2012, Nov-05, Volume: 9, Issue:11

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Calcium Channel Blockers; Camptothecin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Irinotecan; KB Cells; Liver Neoplasms; Male; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Paclitaxel; Piperidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triterpenes; Verapamil

2012
Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
    Journal of controlled release : official journal of the Controlled Release Society, 2013, Mar-10, Volume: 166, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Micelles; Nanoparticles; Prodrugs; Solubility; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays

2013
[Importance and practice of UGT1A1 polymorphisms].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 7

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Female; Glucuronosyltransferase; Humans; Irinotecan; Polymorphism, Genetic

2012
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.
    Journal of gastroenterology and hepatology, 2003, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Diarrhea; Intestine, Small; Irinotecan; Male; Neoplasm Transplantation; Rats; Severity of Illness Index

2003
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
    British journal of cancer, 2003, Nov-03, Volume: 89, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured

2003
[Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:10

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Retrospective Studies; Survival Rate; Taxoids

2003
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    International journal of cancer, 2004, Jan-01, Volume: 108, Issue:1

    Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

2004
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
    Cancer research, 2004, Feb-15, Volume: 64, Issue:4

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan

2004
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].
    MMW Fortschritte der Medizin, 2004, Nov-18, Volume: 146, Issue:47

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A

2004
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Cancer research, 2005, Feb-15, Volume: 65, Issue:4

    Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan

2005
[A case of recurrent breast cancer with bone metastasis causing pancytopenia--efficacy of low-dose CPT-11+ MPA].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Mastectomy, Segmental; Medroxyprogesterone Acetate; Middle Aged; Pancytopenia; Quality of Life

2005
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    International journal of oncology, 2005, Volume: 27, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Protein Serine-Threonine Kinases; Quinazolines; rho-Associated Kinases; Thymidylate Synthase; Time Factors; Topoisomerase I Inhibitors

2005
Expression of drug pathway proteins is independent of tumour type.
    The Journal of pathology, 2006, Volume: 209, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis

2006
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
    Cancer research, 2006, Mar-15, Volume: 66, Issue:6

    Topics: Animals; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Drug Delivery Systems; Drug Stability; Female; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, Nude; Nanostructures; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays

2006
[A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Ductal, Breast; Cardiac Tamponade; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intralesional; Irinotecan; Pericardial Effusion; Pericardiocentesis; Pleural Effusion, Malignant; Pleural Neoplasms

2006
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:5

    Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon-gamma; Irinotecan; Mitoxantrone

2007
Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses.
    Oncology reports, 2007, Volume: 18, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Polymerase Chain Reaction; Stomach Neoplasms; Topoisomerase I Inhibitors

2007
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-15, Volume: 14, Issue:6

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2008
Primary small cell carcinoma of the breast.
    Breast cancer (Tokyo, Japan), 2009, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall

2009
[Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Soft Tissue Neoplasms

1994
Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
    Molecular pharmacology, 1996, Volume: 49, Issue:2

    Topics: Animals; Antineoplastic Agents; Biological Transport; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Nucleus; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Female; Humans; Interleukin-1; Irinotecan; Mice; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Protein Biosynthesis; Recombinant Proteins; Transcription, Genetic; Transplantation, Heterologous

1996
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
    British journal of cancer, 1996, Volume: 74, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Genetic Variation; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Karyotyping; Kinetics; Nuclear Proteins; Tumor Cells, Cultured

1996
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured

1998
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
    Cancer research, 1999, Jul-15, Volume: 59, Issue:14

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cholinesterase Inhibitors; Drug Screening Assays, Antitumor; Esters; Female; Glycine; Humans; Infant, Newborn; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured

1999
Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects.
    British journal of cancer, 1999, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Corn Oil; Drug Synergism; Duodenum; Female; Fish Oils; Gastrointestinal Diseases; Humans; Irinotecan; Lipid Peroxidation; Mice; Mice, Nude; Muscle, Smooth; Thiobarbituric Acid Reactive Substances; Transplantation, Heterologous; Tumor Cells, Cultured

1999
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
    Cancer research, 1999, Dec-01, Volume: 59, Issue:23

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured

1999
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
    Cancer research, 2000, May-01, Volume: 60, Issue:9

    Topics: Adenoviridae; Animals; Apoptosis; Breast Neoplasms; Camptothecin; Cell Nucleus; Colorectal Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Female; Humans; I-kappa B Proteins; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Time Factors; Transgenes; Tumor Cells, Cultured

2000
Highlights of the Eighth European Cancer Conference.
    Journal of the International Association of Physicians in AIDS Care, 1995, Volume: 1, Issue:11

    Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine

1995
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
    Cancer research, 2001, Sep-15, Volume: 61, Issue:18

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus

2001
Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
    Japanese journal of clinical oncology, 2001, Volume: 31, Issue:8

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids

2001
[Globalization of anti-cancer therapies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms

2002
DNA damage is able to induce senescence in tumor cells in vitro and in vivo.
    Cancer research, 2002, Mar-15, Volume: 62, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; beta-Galactosidase; Breast Neoplasms; Camptothecin; Cell Cycle; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; Etoposide; Humans; Irinotecan; Neoadjuvant Therapy; Tumor Suppressor Protein p53

2002
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
    Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:3

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection

2002
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
    International journal of oncology, 2002, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome

2002